EVIDENCE WATCH
A review and assessment of recent clinical trial data

Non-Hodgkin’s lymphoma
FIRST ANALYSIS OF THE COMPLETED MABTHERA INTERNATIONAL (MINT) TRIAL IN YOUNG PATIENTS WITH LOW-RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): ADDITION OF RITUXIMAB TO A CHOP-LIKE REGIMEN SIGNIFICANTLY IMPROVES OUTCOME OF ALL PATIENTS WITH THE IDENTIFICATION OF A VERY FAVORABLE SUBGROUP WITH IPI=O AND NO BULKY DISEASE.

CHIMERIC ANTI-CD20 MONOCLONAL ANTIBODY (RITUXIMAB; MABTHERA) IN REMISSION INDUCTION AND MAINTENANCE TREATMENT OF RELAPSED /RESISTANT FOLLICULAR NON-HODGKIN’S LYMPHOMA: A PHASE III RANDOMIZED INTERGROUP CLINICAL TRIAL.

Chronic myeloid leukemia
HEMATOLOGIC AND CYTOGENETIC RESPONSES IN IMATINIB-RESISTANT CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH THE DUAL SRC/ABL KINASE INHIBITOR BMS-354825: RESULTS FROM A PHASE I DOSE ESCALATION STUDY.

 

To view the clinical trial data of the above topics click here (pdf format)
Back to Top of Page 

 

 
 
 

Oncology Exchange provides overviews of important clinical trial data presented at the 46TH Annual Meeting of the American Society of Hematology (ASH), December 4–7, 2004. Leading Canadian experts offer commentary and clinical interpretations.

 
© Parkhurst Publishing Privacy Statement
Legal Terms of Use
 Site created by Spin Design (514) 995-4398